ALS药物开发指南与试验指南:共识与协调机会
美国FDA于2018年2月发布肌萎缩侧索硬化(ALS)药物开发指南草案,采纳了ALS社区(含临床研究者、企业、患者等)的建议,同时独立修订了ALS临床试验指南。本文讨论三份文件的共识领域及提升药物开发效率的机会,认为生物标志物、疗效终点和预测算法的研究将促进多方协调,持续的患者参与有助于新药获批。
要点
- FDA ALS药物开发指南草案与ALS临床试验指南在多个领域存在共识。
- 生物标志物、疗效终点和预测算法的进一步研究有望提高各方协调性。
- 持续的患者参与和患者体验数据整合可促进新疗法获批。
核心结论
- 三份文件在多个领域达成共识,但仍有提升ALS药物开发效率的空间。
- 生物标志物、疗效终点和预测算法的研究将促进社区利益相关者更大程度协调。
- 持续的患者参与和患者体验数据整合将促进新疗法获批。
研究设计与样本
- 本文为指南类文件,讨论FDA 2018年2月发布的ALS药物开发指南草案、ALS社区建议及独立修订的ALS临床试验指南三份文件。
主要发现
- FDA指南草案采纳了ALS社区(包括临床研究者、行业代表、倡导组织、患者和照护者)的输入。
- ALS社区的外部输入回顾了ALS临床研究现状,就广泛药物开发主题提出建议,并为FDA提供ALS科学现状和社区观点的教育材料。
- 同期独立进行了ALS临床试验指南的修订和更新。
临床怎么用
- 临床医生可关注三份文件在药物开发关键议题上的共识,并了解生物标志物和患者体验数据在试验设计中的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration (FDA) developed a draft guidance for drug development in amyotrophic lateral sclerosis (ALS) that was issued in February 2018. The FDA draft guidance considered the recommendations developed by the ALS community that incorporated the views of a large group of clinical investigators, industry representatives, advocacy groups, patients, and caregivers. This external input from the ALS community reviewed the current state of clinical research in ALS, made suggestions over a wide range of drug development topics, and served as an educational tool to provide the agency with additional inputs about ALS, the state of the science, and the community's views on key topics. In parallel to this effort, there was an independent effort to revise and update the ALS Clinical Trial Guidelines. We discuss the areas of agreement of these 3 documents and the areas that provide opportunities to improve the efficiency of drug development in ALS. It is likely that further research into biomarkers, efficacy endpoints, and predictive algorithms will provide greater alignment among community stakeholders and increase clarity on drug development efforts going forward. Continued patient engagement and inclusion of patient experience data in every aspect of the drug development process will further facilitate the approval of new treatments.
引用
- Andrews JA, Bruijn LI, Shefner JM, et al. ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment. Neurology. 2019. PMID: 31171646. doi:10.1212/WNL.0000000000007695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。